For proficient mismatch repair (pMMR)/microsatellite stability (MSS) metastatic CRC, standard first-line therapy includes fluoropyrimidine-based chemotherapy (with oxaliplatin or irinotecan) or in combination with biological antibodies (anti-vascular endothelial growth factor [VEGF] antibody or anti-epidermal growth factor receptor [EGFR] antibody).7,8 Targeted therapies for patients carrying actionable molecular variations, such as BRAFV600E mutation, KRASG12C mutation, and HER-2 overexpression or amplification, are currently utilised in second-line palliative setting and beyond. The gene discussed is VEGFA; the disease is colorectal carcinoma.